D
Power Law company profile
Deciphera Pharmaceuticals
Biotech & Life Sciences · Waltham, United States · Founded 2003 · IPO 2017 Unicorn
Valuation
$1.97B
Market cap · 2026
Revenue
$170M
Latest reported FY
Global footprint
Where Deciphera Pharmaceuticals has talent and traffic
AI talent share
0.4%
of workforce is AI talent
(2 of 535 staff)
(2 of 535 staff)
Core AI10.19%
Other AI10.19%
Non-AI workforce53399.63%
Web traffic by country
13K
monthly visits
across markets
across markets
🇺🇸 United States66.9%
🇬🇧 United Kingdom12.3%
🇯🇵 Japan11.5%
🇨🇦 Canada7.7%
🇮🇹 Italy1.5%
Patent intelligence
$133M patent portfolio · 112 active families
Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with quality scores compared against same-sector peers.
Estimated portfolio value
$133M
6.8% of market cap · 3.4× the top peer TESARO ($39M)
112 active patent families
Where Deciphera Pharmaceuticals innovates
Cancer researchMolecular biologyCarcinosisDiseaseKinase inhibition
Below peer median on Market
Quality vs same-sector peers
Deciphera Pharmaceuticals on the five Patsnap quality dimensions
Deciphera Pharmaceuticals in orange. Same-sector peers are the top filers by total patent value. All scores 0–100; higher is stronger.
Compare against
Patent quality scores (0–100)
Source: Dealroom Patent Intelligence · PatsnapTech-focus vs peers
Where Deciphera Pharmaceuticals concentrates inside the peer cluster
Axes are the most-shared Patsnap topics across Deciphera Pharmaceuticals and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).
Compare against
Top-topic prominence (rank inverted, 0–100)
Source: Dealroom Patent Intelligence · Patsnap top-10 topics per companySee Deciphera Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.